甲状腺髓样癌的治疗

doi:10.3760/cma.j.issn.1673-422X.2014.08.008

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (8): 582-585.doi: 10.3760/cma.j.issn.1673-422X.2014.08.008

甲状腺髓样癌的治疗

毕娅兰,孟云霄,崔全才

100730 北京，中国医学科学院北京协和医院病理科

收稿日期:2014-01-14 修回日期:2014-05-14 出版日期:2014-08-15 发布日期:2014-08-14
通讯作者: 崔全才，E-mail:cuiqc@sina.com E-mail:cuiqc@sina.com

Treatment strategy for medullary thyroid cancer

Bi Yalan, Meng Yunxiao, Cui Quancai

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Received:2014-01-14 Revised:2014-05-14 Online:2014-08-15 Published:2014-08-14
Contact: Cui Quancai E-mail:cuiqc@sina.com

摘要/Abstract

摘要： 甲状腺髓样癌是一种少见的甲状腺恶性肿瘤，由于其起源于甲状腺滤泡旁C细胞，故与针对其他常见的甲状腺肿瘤如甲状腺乳头状癌等的治疗方法有所不同，具有自身的特点。近年来，使用酪氨酸激酶抑制剂的靶向治疗为甲状腺髓样癌的治疗带来了新希望。

关键词: 甲状腺肿瘤, 外科手术, 放射性同位素, 放射疗法, 分子靶向治疗

Abstract: Medullary thyroid cancer is a kind of rare malignancy arising from unregulated replication of parafollicular C cells of the thyroid gland. Therapeutic approaches to patients with medullary thyroid cancer have their own features, which are different from those to patients with papillary thyroid cancer, the most common type of thyroid cancer. The targeted therapy using tyrosine kinase inhibitors has brought new hope for the management of aggressive medullary thyroid cancer in recent years.

Key words: Thyroid neoplasms, Surgical procedures, Radioisotopes, Radiotherapy, Molecular targeted therapy

毕娅兰,孟云霄,崔全才. 甲状腺髓样癌的治疗[J]. 国际肿瘤学杂志, 2014, 41(8): 582-585.

Bi Yalan, Meng Yunxiao, Cui Quancai. Treatment strategy for medullary thyroid cancer[J]. Journal of International Oncology, 2014, 41(8): 582-585.

参考文献

［1］ Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments［J］. Curr Opin Oncol, 2011, 23(1): 22-27. ［2］ Figlioli G, Landi S, Romei C, et al. Medullary thyroid carcinoma (MTC) and RET protooncogene: mutation spectrum in the familial cases and a metaanalysis of studies on the sporadic form［J］. Mutat Res, 2013, 752(1): 36-44. ［3］ Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 yearsexperience on 157 patients［J］. Eur J Surg Oncol, 2007, 33(4): 493-497. ［4］ Stamatakos M, Paraskeva P, Katsaronis P, et al. Surgical approach to the management of medullary thyroid cancer: when is lymph node dissection needed?［J］ . Oncology, 2013, 84(6): 350-355. ［5］ Kandil E, Gilson MM, Alabbas HH, et al. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer［J］. Ann Surg Oncol, 2011, 18(4): 1028-1034. ［6］ Dequanter D, Lothaire P. Medullary thyroid cancer: surgical results and prognostic factors［J］. Rev Med Liege, 2010, 65(7-8): 450-452. ［7］ Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer［J］. Br J Surg, 2008, 95(5): 586-591. ［8］ American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association［J］. Thyroid, 2009, 19(6): 565-612. ［9］ Sugawara M, Ly T, Hershman JM. Medullary thyroid cancercurrent treatment strategy, novel therapies and perspectives for the future［J］. Horm Cancer, 2012, 3(56): 218-226. ［10］ Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases［J］. Cancer, 2006, 107(9): 2134-2142. ［11］ Meijer JA, le Cessie S, van den HoutWB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured metaanalysis［J］. Clin Endocrinol(Oxf), 2010, 72(4): 534-542. ［12］ Sugawara M, Geffner DL, Martinez D, et al. Novel treatment of medullary thyroid cancer［J］. Curr Opin Endocrinol Diabetes Obes, 2009, 16(5): 367372. ［13］ Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10year followup study［J］. J Clin Endocrinol Metab, 2008, 93(3): 682-687. ［14］ Capp C, Wajner SM, Siqueira DR, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR1 and VEGFR2, in medullary thyroid carcinoma［J］. Thyroid, 2010, 20(8): 863-871. ［15］ Campbell MJ, Seib CD, Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer［J］. Curr Opin Oncol, 2013, 25(1): 39-43. ［16］ Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, doubleblind phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(2): 134-141. ［17］ Haraldsdottir S, Shah MH. An update on clinical trials of targeted therapies in thyroid cancer［J］. Curr Opin Oncol, 2014, 26(1): 36-44. ［18］ Bodei L, HandkiewiczJunak D, Grana C, et al. Receptor radionuclide therapy with 90YDOTATOC in patients with medullary thyroid carcinomas［J］. Cancer Biother Radiopharm, 2004, 19(1): 65-71. ［19］ Vainas I, Koussis Ch, PazaitouPanayiotou K, et al. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma［J］. J Exp Clin Cancer Res, 2004, 23(4): 549-559. ［20］ Vitale G, Lupoli G, Guarrasi R, et al. Interleukin2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies［J］. J Clin Endocrinol Metab, 2013, 98(10): E1567-1574. ［21］ Martinez SR, Beal SH, Chen A, et al. Adjuvant external beam radiation for medullary thyroid carcinoma［J］. J Surg Oncol, 2010, 102(2): 175-178. ［22］ Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancerlocal disease control in the modern era［J］. Head Neck, 2008, 30(7): 883-888.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[6]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[7]	王子琪, 罗盼, 叶永英, 吴伟莉. 甲状腺腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(3): 191-192.
[8]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[9]	杨博, 付茂勇. 单孔胸腔镜下左上肺舌段癌袖式切除同期行右肺上叶癌切除术1例[J]. 国际肿瘤学杂志, 2024, 51(2): 126-128.
[10]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[11]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[12]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[13]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[14]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[15]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.

甲状腺髓样癌的治疗

Treatment strategy for medullary thyroid cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价